Retatrutide (GLP-3) Dosing: What the Phase 3 Trials Actually Show

Direct Answer

Retatrutide's Phase 3 TRIUMPH-1 trial tested three dose levels, 4mg, 9mg, and 12mg, weekly. Since retatrutide is not yet FDA-approved, there is no official, finalized prescribing dose or titration schedule, this data reflects clinical trial protocols, not an approved treatment regimen. What the trial data does show clearly is a real, dose-dependent tradeoff, higher doses produced meaningfully greater weight loss, but also higher rates of gastrointestinal side effects and treatment discontinuation.

Weight Loss by Dose Level

At the lowest tested dose, 4mg, participants achieved an average 19.0% weight loss over 80 weeks. At the highest tested dose, 12mg, average weight loss reached 28.3% at 80 weeks and 30.3% at 104 weeks, results described by researchers as approaching bariatric surgery-level outcomes.

The Real Tradeoff: Tolerability by Dose

Discontinuation due to adverse events rose consistently with dose: 4.1% at 4mg, 6.9% at 9mg, and 11.3% at 12mg, compared to a 4.9% placebo discontinuation rate. Notably, the lowest dose actually showed a lower discontinuation rate than placebo, while still producing substantial weight loss, a genuinely favorable tolerability signal specifically at the lower end of dosing. Nausea followed the same pattern: 28.6% at 4mg, rising to 42.4% at 12mg.

Why This Matters for Understanding the Medication

This dose-response relationship, more effect at higher doses, but more side effects too, is a pattern seen across the entire GLP-1 medication class, not unique to retatrutide. What stands out here is how clearly it's documented, retatrutide's trial design specifically tested multiple discrete dose levels, giving genuinely useful comparative data on exactly where that tradeoff sits.

What's Still Unknown

Since retatrutide remains investigational, there's no confirmed, official titration schedule (the step-by-step process of increasing dose over time) the way there is for FDA-approved medications like Ozempic or Mounjaro. Once and if the medication receives FDA approval, an official prescribing schedule would be established as part of that process, likely informed directly by this same trial data.

Bottom Line

The real, documented pattern from Phase 3 data: lower doses of retatrutide offer meaningful weight loss with tolerability comparable to or better than placebo, while higher doses offer substantially greater results at the cost of more frequent side effects and higher discontinuation. This tradeoff, not a single "right" dose, is what the actual trial data shows.

References

• AJMC: Retatrutide Achieves Up to 30.3% Average Weight Loss in Phase 3 TRIUMPH-1 Trial
• Pharmacy Times: Retatrutide Delivers Bariatric-Level Weight Loss in Pivotal Phase 3 TRIUMPH-1 Trial
• The Pharmaceutical Journal: Phase III Retatrutide Study Demonstrates 30% Weight Loss (May 2026)

Related Resources

• Retatrutide Medication Guide
• Retatrutide (GLP-3) Side Effects: What Phase 3 Trial Data Actually Shows
• The TRIUMPH Trials: Retatrutide's Investigational Evidence
• Is Retatrutide FDA-Approved Yet? Current Status

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Track retatrutide alongside every other GLP-1 medication on DietApp.com.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. Retatrutide is investigational and not FDA-approved; no official dosing schedule currently exists. This article is for general informational purposes and is not medical advice.